确立肝功能失代偿作为肝细胞癌系统治疗中有意义的临床结局
晚期肝细胞癌预后受肿瘤进展与肝功能障碍双重影响,临床显性失代偿事件对预后影响可能比肿瘤进展更深远。在高效免疫治疗时代,部分肝功能受损或门脉高压患者也可接受治疗,但失代偿风险高,需制定预防和管理策略。未来试验应将肝功能失代偿作为有临床意义和预后相关性的中间终点,以研究失代偿与肿瘤进展对总生存的竞争效应。
要点
- 肝细胞癌预后受肿瘤进展与肝功能障碍双重影响,失代偿事件影响可能更显著。
- 高效免疫治疗可用于肝功能受损或门脉高压患者,但失代偿风险高。
- 未来试验应将失代偿作为中间终点,研究其与肿瘤进展对总生存的竞争效应。
核心结论
- 肝功能失代偿是肝细胞癌系统治疗中有临床意义且预后相关的结局,应纳入未来试验作为中间终点。
研究设计与样本
- 本文为针对肝细胞癌系统治疗中肝功能失代偿作为临床结局的论述性文章,未报告系统检索范围或样本量。
主要发现
- 临床显性肝功能失代偿事件对肝细胞癌患者预后的影响比肿瘤进展更深远。
关键数值与推荐
- 对基础病因进行严格诊断检查并治疗,可能实现肝硬化再代偿。
- 对存在门脉高压的患者使用非选择性β受体阻滞剂。
临床怎么用
- 临床实践应采用整合多方面的治疗策略,同时处理基础肝病和叠加的肿瘤,以优化患者总体结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Unlike other solid tumours, the prognosis of patients with advanced hepatocellular carcinoma (HCC) is dually influenced by tumour progression and liver dysfunction. Accumulating evidence suggests that clinically evident hepatic decompensating events impact on the prognosis of patients with HCC more profoundly than tumour progression. This observation is particularly relevant in the new era of highly effective immunotherapy, which can also be administered to patients with impaired hepatic function (i.e. higher albumin-bilirubin [ALBI] grade) and/or with clinical signs of portal hypertension, both indicating a high risk of hepatic decompensation. Thus, it is of the utmost clinical importance to develop practical strategies for prevention and management of decompensation in patients with HCC, which include a rigorous diagnostic workup and treatment of the underlying disease aetiology - which may allow for cirrhosis recompensation - and the use of non-selective beta blockers in those with portal hypertension. We propose that future trials should incorporate hepatic decompensation as a clinically meaningful and prognostically relevant intermediate endpoint to investigate the competing effects of decompensation and tumour progression on overall survival - the gold standard endpoint for the regulatory approval of systemic HCC therapy. Clinical practice should adopt an integrated and multifaceted treatment approach that addresses both the underlying liver disease and the superimposed cancer to optimise overall patient outcomes in the context of expanding therapeutic options.
引用
- Cabibbo G, Celsa C, Bhoori S, et al. Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma. J Hepatol. 2025. PMID: 40759204. doi:10.1016/j.jhep.2025.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。